Taletrectinib for Non-Small Cell Lung Cancer

Phase-Based Progress Estimates
Hospital General de Catalunya, Barcelona, SpainNon-Small Cell Lung CancerTaletrectinib - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is studying taletrectinib to see how well it works in treating patients with non-small cell lung cancer.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: Up to 4 years

Up to 4 years
Efficacy endpoints assessed by investigators
Intracranial objective response rate (IC-ORR)
Intracranial progression-free survival (IC-PFS)
Objective response rate (ORR) assessed by investigators
Objective response rate (ORR) by independent radiology review committee (IRC)
Pharmacokinetic (PK) profile of taletrectinib
Progression-free survival (PFS)
Safety and tolerability of taletrectinib

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

1 of 1

Experimental Treatment

154 Total Participants · 1 Treatment Group

Primary Treatment: Taletrectinib · No Placebo Group · Phase 2

Experimental Group · 1 Intervention: Taletrectinib · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 4 years

Who is running the clinical trial?

AnHeart Therapeutics Inc.Lead Sponsor
8 Previous Clinical Trials
422 Total Patients Enrolled
Lian LiStudy DirectorAnHeart Therapeutics Inc.
Study DirectorStudy DirectorAnHeart Therapeutics Inc.
1,089 Previous Clinical Trials
483,746 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 14 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You can be included in the study whether or not you have received treatment for ROS1 with medication before.

Who else is applying?

What state do they live in?
How old are they?
18 - 65100.0%
What site did they apply to?
American Institute of Research100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%

Frequently Asked Questions

Are there any openings for new participants in this trial?

"Absolutely. Evidence from clinicaltrials.gov confirms that this research, which was first published on September 1st 2021, is still recruiting subjects. A total of 119 participants are needed across 25 distinct medical sites." - Anonymous Online Contributor

Unverified Answer

What is the scope of enrolment for this research project?

"AnHeart Therapeutics Inc. need to enlist 119 participants that meet their study's criteria, and are running the trial from multiple sites such as Keck Medicine of University of Southern California in LA and Moores Cancer Center at UC San Diego in La Jolla, Minnesota." - Anonymous Online Contributor

Unverified Answer

What deleterious effects have been observed when taking Taletrectinib?

"We at Power assign a safety rating of 2 to taletrectinib, as there is some evidence backing its safe use but none that speaks to efficacy." - Anonymous Online Contributor

Unverified Answer

How many healthcare settings are participating in this trial?

"This trial has 25 active clinical sites including Keck Medicine of University of Southern California in Los Angeles, Moores Cancer Center at UC San Diego in La Jolla and Mayo Clinic in Rochester. Additionally, there are 22 other operating centres." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.